BACTERICIDAL ACTIVITY OF HUMAN PERITONEAL-MACROPHAGES FROM PATIENTS UNDERGOING PERITONEAL-DIALYSIS

被引:0
|
作者
THOMAS, CA
INTERWIES, EW
ZIEGLER, BL
VLACHOJANIS, J
KURZ, P
SHAH, PM
机构
关键词
HUMAN PERITONEAL MACROPHAGES; PERITONEAL DIALYSIS; POLYMORPHONUCLEAR LEUKOCYTES; ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; STAPHYLOCOCCUS-EPIDERMIDIS; PSEUDOMONAS-AERUGINOSA;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Peritoneal macrophages (PM) play an essential role in the pathogenesis of bacterial peritonitis, the main complication of peritoneal dialysis (PD). We determined the antibacterial activity of PM from 31 PD patients using gram-positive (Staphylococcus aureus, Staphylococcus epidermidis) and gram-negative (Escherichia coli, Pseudomonas aeruginosa) test organisms. In an 8-hour test assay, PM revealed the highest antibacterial activity against E. coli [median bactericidal index (B(i)) = 5.46 representing 0.74 log growth inhibition compared to controls] and the lowest against P. aeruginosa (B(i) = 1.63, 0.21 log growth inhibition, p < 0.05). The antibacterial activity against S. aureus (B(i) = 1.99, 0.3 log growth inhibition) and S. epidermidis (B(i) = 2.0, 0.31 log growth inhibition) was within this range. When compared to peripheral blood polymorphonuclear leukocytes, PM reached only 4% (S. aureus) and 8.1% (E. coli) of their antibacterial activity (p < 0.05). Using E. coli as a test organism, PM isolated after a 4-hour dialysis period revealed the highest antibacterial activity when compared to PM isolated after longer dialysis periods (p < 0.05). Increasing the duration of PD to 6 and 8 h subsequently decreased the antibacterial activity of PM, suggesting that unphysiologic concentrations of toxic metabolites in the peritoneal effluent might have a harmful influence on PM functions.
引用
收藏
页码:12 / 18
页数:7
相关论文
共 50 条
  • [21] PHARMACOKINETICS OF TOBRAMYCIN IN PATIENTS UNDERGOING PERITONEAL-DIALYSIS
    RAMOS, E
    ADIR, JA
    SHEN, YL
    LESLIE, J
    ATKINS, J
    SADLER, JH
    KIDNEY INTERNATIONAL, 1979, 16 (06) : 896 - 896
  • [22] PHARMACOKINETICS OF METRONIDAZOLE IN PATIENTS UNDERGOING PERITONEAL-DIALYSIS
    CASSEY, JG
    CLARK, DA
    MERRICK, P
    JONES, B
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 24 (06) : 950 - 951
  • [23] PHARMACOKINETICS OF CEFTAZIDIME IN PATIENTS UNDERGOING PERITONEAL-DIALYSIS
    TOURKANTONIS, A
    NICOLAIDIS, P
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1983, 12 : 263 - 267
  • [24] ANALYSIS OF PERITONEAL MONOCYTES FROM PATIENTS UNDERGOING CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS (CAPD)
    GOLDSTEIN, C
    DOUGLAS, S
    MORRISON, G
    NEILSON, E
    KIDNEY INTERNATIONAL, 1984, 25 (01) : 256 - 256
  • [25] PHARMACOLOGY OF INTRA-PERITONEAL CEFAZOLIN IN PATIENTS UNDERGOING PERITONEAL-DIALYSIS
    KAYE, D
    WENGER, N
    AGARWAL, B
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1978, 14 (03) : 318 - 321
  • [26] PERITONEAL-FLUID EOSINOPHILIA IN PATIENTS UNDERGOING MAINTENANCE PERITONEAL-DIALYSIS
    HUMAYUN, HM
    ING, TS
    DAUGIRDAS, JT
    GANDHI, VC
    POPLI, S
    ROBINSON, JA
    HANO, JE
    ZAYAS, I
    ARCHIVES OF INTERNAL MEDICINE, 1981, 141 (09) : 1172 - 1173
  • [27] PERITONEAL SCLEROSIS IN PERITONEAL-DIALYSIS PATIENTS
    ING, TS
    DAUGIRDAS, JT
    GANDHI, VC
    AMERICAN JOURNAL OF NEPHROLOGY, 1984, 4 (03) : 173 - 176
  • [28] EFFECT OF CLINDAMYCIN ON THE INTRACELLULAR BACTERICIDAL CAPACITY OF HUMAN PERITONEAL-MACROPHAGES
    DEFIJTER, CWH
    VERBRUGH, HA
    HEEZIUS, HCJM
    VANDERMEULEN, J
    OE, PL
    DONKER, AJM
    VERHOEF, J
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 26 (04) : 525 - 532
  • [29] EFFECT OF PERITONEAL-DIALYSIS FLUID AND PH ON BACTERICIDAL ACTIVITY OF CIPROFLOXACIN
    MCCORMICK, EM
    ECHOLS, RM
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (04) : 657 - 659
  • [30] EXPRESSION OF TRANSFERRIN RECEPTORS BY MONOCYTES AND PERITONEAL-MACROPHAGES FROM RENAL-FAILURE PATIENTS TREATED BY CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS (CAPD)
    MOUGHAL, NA
    MCGREGOR, SJ
    BROCK, JH
    BRIGGS, JD
    JUNOR, BJR
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1991, 21 (06) : 592 - 596